HealthQuill pfizer
The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in people 18-59 years.
Pharma

Pfizer to invest $1b in China over five years, strengthens biotech footprint

HQ Times November 8, 2024: Pfizer under activist investor pressure is busy turning its performance around and has decided to expand its presence.

Read More
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season compared to 94.1% in the first and 64.2% in the second.
Drugs Health Pharma

GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year

GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.

Read More
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in 27 member states and other nations.
Drugs Health Pharma

EC approves Merck’s bladder cancer combination therapy in adults 

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.

Read More
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.
Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

Read More
Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,” after a single jab, according to a company statement. 
Drugs Health Pharma

‘Strong neutralizing responses’ shown in RSV vaccine trials: Pfizer says

Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,”.

Read More
Pfizer’s haemophilia A gene therapy has reduced bleeding rates in patients during an end-stage trial, according to a company statement.
Drugs Health Pharma

Pfizer’s haemophilia A gene therapy cuts bleeding rates during trials

HQ Team July 25, 2024: Pfizer’s haemophilia A gene therapy has reduced bleeding rates in patients during an end-stage trial, according to a.

Read More
The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six months and older, according to a joint statement.
Drugs Health Pharma

Pfizer, BioNTech gets EMA marketing nod for variant Covid-19 vaccine

The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six.

Read More
Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to a statement.
Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.
Drugs Health Pharma

Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal

Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.

Read More
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression after five years, according to company data.
Drugs Health Pharma

Pfizer’s drug helps people with rare lung cancer live longer, data shows

Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.

Read More